Tirzepatide Injection Guide: How to Inject Mounjaro & Zepbound (2026)

Overview

Tirzepatide is administered as a once-weekly subcutaneous injection using a pre-filled, single-dose pen device. Whether you are using Mounjaro (for type 2 diabetes) or Zepbound (for weight management), the injection technique, pen operation, and dose titration schedule are identical. The pen device is designed for ease of use and does not require dose measurement, reconstitution, or handling of loose needles — the needle is built into the pen and is hidden before, during, and after injection. This guide covers every aspect of the injection process: pen components and operation, proper injection technique, injection site selection and rotation, the complete dose titration schedule, storage requirements, what to do if you miss a dose, and the most common mistakes that can reduce efficacy or cause complications. This information supplements — but does not replace — the instructions provided by your healthcare provider and the manufacturer's patient information leaflet included with your medication.

Understanding Your Tirzepatide Pen Device

The Mounjaro and Zepbound auto-injector pens are single-dose, disposable devices that contain one pre-measured dose of tirzepatide. Each pen is used once and then discarded — there are no refills or reusable components. The pen design incorporates a hidden needle system: you never see, touch, or manually attach a needle. The needle extends automatically when the pen is activated and retracts automatically after the injection is complete, which reduces the risk of needlestick injuries and makes the device accessible to people with needle anxiety. Each pen has two main components visible to the user: a gray base cap on the bottom that covers the hidden needle, and a purple injection button on the top. The clear base at the bottom allows you to see the medication inside — it should appear clear and colorless to slightly yellow. Do not use the pen if the medication appears cloudy, discolored, or contains visible particles. Each pen is color-coded by dose strength, making it easy to confirm you are using the correct dose: turquoise for 2.5 mg, purple for 5 mg, dark gray for 7.5 mg, green for 10 mg, dark blue for 12.5 mg, and plum for 15 mg. Before first use, each pen should be removed from the refrigerator and allowed to reach room temperature for approximately 30 minutes. Injecting cold medication can increase discomfort at the injection site. Do not use a microwave, hot water, or any external heat source to warm the pen — simply set it on a clean surface at room temperature. Check the expiration date printed on the pen and outer carton before each injection. Do not use the pen if it has expired. Also inspect the pen for any visible damage — cracks, leaks, or a loose base cap — and discard any pen that appears compromised.

• Single-dose, disposable pen — one pen per injection, no refills or reusable parts
• Hidden needle system — needle extends automatically during injection and retracts afterward; you never see or handle the needle directly
• Gray base cap — remove before injection; covers the hidden needle area
• Purple injection button — press and hold to start the injection; you will hear two clicks (start and finish)
• Clear base — allows visual inspection of the medication; should be clear and colorless to slightly yellow
• Color-coded by dose: turquoise (2.5 mg), purple (5 mg), dark gray (7.5 mg), green (10 mg), dark blue (12.5 mg), plum (15 mg)
• Allow 30 minutes at room temperature before injecting for comfort — never use external heat to warm the pen

Step-by-Step Injection Technique

Proper injection technique ensures that the full dose is delivered subcutaneously (into the fat layer beneath the skin) and minimizes discomfort and complications. The injection process takes approximately 5-10 seconds of active injection time, plus preparation. Begin by washing your hands thoroughly with soap and water. Remove the pen from the refrigerator and let it sit at room temperature for 30 minutes. While waiting, prepare your injection site by cleaning the area with an alcohol swab and allowing it to air dry — do not blow on it or fan it, as this can introduce bacteria. When ready, hold the pen with the gray base cap pointing down. Pull the gray base cap straight off — do not twist it. You may see a small drop of medication at the needle tip, which is normal and does not affect your dose. Place the clear base flat against your cleaned skin at the injection site. You do not need to pinch the skin unless you are very lean (less than approximately 1 inch of subcutaneous fat at the injection site). Unlock the pen by turning the lock ring from the locked position to the unlocked position (this is a quarter-turn safety mechanism). Press and hold the purple injection button firmly. You will hear a first click, which indicates the injection has started. Continue holding the pen against your skin — the injection is not complete at the first click. A second click will sound approximately 5-10 seconds later, indicating the injection is complete. After the second click, slowly count to five while continuing to hold the pen against your skin, then lift the pen straight away from the injection site. The needle will retract automatically. You should see that the gray plunger is visible in the clear base, confirming the full dose has been delivered. If you do not see the gray plunger, the dose may not have been fully delivered — contact your healthcare provider for guidance. Dispose of the used pen in a sharps container. Do not reuse the pen, recap it, or throw it in regular household trash.

• Step 1: Wash hands with soap and water; remove pen from refrigerator 30 minutes before injection
• Step 2: Clean injection site with alcohol swab; allow to air dry completely
• Step 3: Pull gray base cap straight off (do not twist); a drop of medication at the tip is normal
• Step 4: Place clear base flat against skin at injection site; skin pinching is generally not needed unless very lean
• Step 5: Turn the lock ring to unlock the pen (quarter-turn safety mechanism)
• Step 6: Press and hold the purple button; first click = injection started; keep holding against skin
• Step 7: Second click = injection complete; continue holding for 5 additional seconds, then lift pen straight away
• Step 8: Verify gray plunger is visible in clear base (confirms full dose delivery); dispose in sharps container

Injection Sites and Rotation Strategy

Tirzepatide can be injected into three approved subcutaneous injection sites: the abdomen, the front of the thigh, and the back of the upper arm. Each site has specific considerations for comfort, absorption, and practical ease of self-administration. The abdomen is the most commonly used site and is generally considered the most comfortable option for self-injection. The recommended injection area is the lower abdomen, at least 2 inches (5 cm) away from the navel, avoiding the area directly around the navel and any areas with scars, bruises, or skin abnormalities. The abdomen offers a relatively large surface area with ample subcutaneous fat in most individuals, making it easy to rotate positions between injections. Absorption from the abdomen tends to be consistent and is the most studied site in clinical trials. The front of the thigh is another accessible self-injection site. Use the upper outer area of the thigh, approximately midway between the hip and the knee. Avoid injecting into areas with prominent veins, scar tissue, or the inner thigh. The thigh may have slightly variable absorption rates compared to the abdomen depending on the amount of subcutaneous fat at the specific injection location, but this has not been shown to be clinically significant for tirzepatide. The back of the upper arm is a viable injection site but is difficult to self-administer — this site is primarily practical when a caregiver or partner is administering the injection. Use the outer, fleshy area of the upper arm between the shoulder and elbow. Site rotation is important for preventing lipodystrophy — localized changes in subcutaneous fat tissue that can occur with repeated injections in the same area. Lipodystrophy can manifest as either lipohypertrophy (thickening of fat tissue, creating bumps or lumps) or lipoatrophy (loss of fat tissue, creating indentations). Both conditions can alter medication absorption from the affected area, potentially leading to inconsistent drug levels. Rotate injection sites systematically: do not inject in the same spot two weeks in a row, and ideally alternate between different body regions (e.g., left abdomen one week, right thigh the next, left abdomen the following week). When using the same body region, vary the exact injection location by at least 1-2 inches from the previous site. A simple rotation pattern — such as moving clockwise around the abdomen or alternating left and right thighs — makes it easy to avoid repeating locations.

• Abdomen: Most common and comfortable site; inject at least 2 inches from navel; large area for rotation
• Front of thigh: Upper outer area between hip and knee; accessible for self-injection; avoid inner thigh and veins
• Back of upper arm: Outer fleshy area; practical primarily for caregiver-administered injections due to self-access difficulty
• Rotate sites weekly: Never inject the same exact spot two weeks in a row; alternate between body regions or vary position by 1-2 inches
• Avoid: areas with scars, bruises, redness, rashes, lumps, or skin abnormalities
• Lipodystrophy prevention: Systematic rotation prevents fat tissue changes that can alter medication absorption

Dose Titration Schedule: 2.5 mg to 15 mg

Tirzepatide uses a gradual dose titration (escalation) schedule designed to minimize gastrointestinal side effects — primarily nausea, which is the most common adverse event during treatment initiation and dose increases. The titration schedule is the same for both Mounjaro and Zepbound and is based on the protocols used in the SURPASS and SURMOUNT clinical trials. The starting dose is 2.5 mg once weekly for the first 4 weeks. This dose is not intended as a treatment dose — it is a tolerability dose designed to allow your body to adjust to the medication's effects on gastric emptying and appetite regulation. Some patients experience weight loss at the 2.5 mg dose, but the primary goal of this initial phase is to establish tolerance. After 4 weeks at 2.5 mg, the dose increases to 5 mg once weekly. This is the first treatment dose, meaning it has demonstrated therapeutic efficacy in clinical trials. Many patients experience a noticeable increase in appetite suppression and weight loss at 5 mg. Gastrointestinal side effects — particularly nausea — may temporarily increase with this dose escalation. Subsequent dose increases occur in 2.5 mg increments every 4 weeks, following the pattern: 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. However, dose increases beyond 5 mg are not mandatory — they are based on individual response and tolerability. Your healthcare provider should guide the decision to increase, maintain, or slow the titration based on your weight loss trajectory, glycemic control (if treating diabetes), side effect burden, and treatment goals. The maximum approved dose is 15 mg once weekly. In the SURMOUNT-1 trial, the 15 mg dose produced mean weight loss of 22.5% at 72 weeks — the highest of any anti-obesity medication. However, not all patients need or tolerate the maximum dose, and meaningful clinical benefit occurs at lower doses as well. The 10 mg dose produced 19.5% weight loss and the 5 mg dose produced 15% in the same trial. A common mistake is escalating the dose too quickly in pursuit of faster results. Rapid escalation significantly increases the risk and severity of gastrointestinal side effects, which can lead to dehydration, electrolyte imbalances, and treatment discontinuation. Patience during titration produces better long-term outcomes than aggressive escalation.

• Weeks 1-4: 2.5 mg weekly (tolerability dose — not a therapeutic dose; allows GI system to adjust)
• Weeks 5-8: 5 mg weekly (first therapeutic dose; increased appetite suppression and weight loss)
• Weeks 9-12: 7.5 mg weekly (optional increase based on response and tolerability)
• Weeks 13-16: 10 mg weekly (continue if additional efficacy needed and prior dose tolerated)
• Weeks 17-20: 12.5 mg weekly (continue based on clinical response)
• Week 21+: 15 mg weekly (maximum dose; highest efficacy in clinical trials — 22.5% weight loss at 72 weeks)
• Dose increases are clinician-guided — not all patients need to reach 15 mg; significant benefit occurs at 5-10 mg
• Do not increase dose faster than every 4 weeks; rushing titration increases nausea risk and treatment dropout

Storage, Handling, and Missed Doses

Proper storage of tirzepatide is critical because it is a biologic peptide medication that can degrade if exposed to inappropriate temperatures, light, or physical stress. Before first use, tirzepatide pens must be stored in the refrigerator at 36 to 46 degrees Fahrenheit (2 to 8 degrees Celsius). Do not freeze tirzepatide — if a pen has been frozen, it must be discarded even if it has thawed, as freezing can damage the protein structure of the peptide and compromise efficacy. Keep pens in their original carton to protect from light. Unopened pens can be stored in the refrigerator until the expiration date printed on the carton. If needed, an unopened pen can be stored at room temperature (up to 86 degrees Fahrenheit or 30 degrees Celsius) for a cumulative total of up to 21 days. This is useful for travel or situations where refrigeration is temporarily unavailable. Once the 21-day room temperature window has passed, the pen must be discarded even if it has not been used. Track the date you remove the pen from the refrigerator to ensure you use it within the 21-day window. Do not store tirzepatide in direct sunlight, in a car glove compartment or trunk (where temperatures can exceed safe ranges), or in a bathroom medicine cabinet (where humidity and temperature fluctuate). When traveling, use an insulated medication travel case with cold packs — but ensure the cold packs are not in direct contact with the pen, as this could cause localized freezing. For missed doses, the guidance depends on how much time has elapsed since the missed injection. If your dose is missed and fewer than 4 days (96 hours) have passed since the scheduled injection day, inject the missed dose as soon as possible. If more than 4 days have passed, skip the missed dose and inject the next dose on your regularly scheduled day. Do not inject two doses at the same time or within the same week to make up for a missed dose. Missing occasional doses is common and generally does not require restarting the titration schedule — simply resume at your current dose on the next scheduled day. However, if you miss multiple consecutive weeks (generally two or more), consult your healthcare provider about whether to resume at your current dose or step back to a lower dose to re-establish tolerability.

• Refrigerator storage: 36-46 degrees F (2-8 degrees C); keep in original carton to protect from light; do not freeze
• Room temperature storage: Up to 86 degrees F (30 degrees C) for a maximum of 21 cumulative days; discard after 21 days even if unused
• Never freeze: Frozen pens must be discarded even if thawed — freezing damages the peptide structure
• Light protection: Keep in original carton; avoid direct sunlight and fluorescent light exposure
• Missed dose (less than 4 days late): Inject as soon as possible; resume regular schedule on next scheduled day
• Missed dose (more than 4 days late): Skip the missed dose; inject next dose on your regular day
• Never double dose: Do not inject two doses in the same week to compensate for a missed dose
• Multiple missed weeks: Consult your provider about whether to resume at current dose or step back for re-titration

Common Injection Mistakes and How to Avoid Them

Even with a well-designed auto-injector pen, there are several common mistakes that can reduce the effectiveness of your tirzepatide injection, increase discomfort, or cause complications. Understanding these pitfalls helps you optimize your injection technique from the start. The most impactful mistake is removing the pen from the skin too early — before the second click sounds and the full 5-second hold after the second click is completed. The injection takes approximately 5-10 seconds of active delivery time. If you lift the pen away before the dose is fully delivered, you may receive a partial dose, and there is no way to re-administer the remaining medication from a used pen. If you are uncertain whether the full dose was delivered, check for the gray plunger visible in the clear base window — if it is visible, the dose was complete. Injecting cold medication directly from the refrigerator is another common mistake. Cold medication causes more discomfort at the injection site and may lead to injection site reactions. Always allow the pen to sit at room temperature for at least 30 minutes before injection. However, do not leave the pen at room temperature for more than 21 cumulative days. Failing to rotate injection sites is a mistake with longer-term consequences. Repeatedly injecting in the same location can cause lipodystrophy, which alters local fat tissue and can affect medication absorption, leading to inconsistent blood levels and unpredictable efficacy. Using a systematic rotation schedule prevents this. Injecting into muscle rather than subcutaneous tissue can occur in very lean individuals who do not pinch the skin to create a subcutaneous fold, or who inject in areas with minimal subcutaneous fat. Intramuscular injection leads to faster absorption, which can increase side effects and alter the drug's pharmacokinetic profile. If you are very lean, pinch a fold of skin at the injection site and inject into the pinched fold. Improper disposal of used pens poses a safety risk. Used pens contain a retracted but potentially sharp needle and should be placed in a sharps disposal container — not thrown in regular household trash. Sharps containers are available at pharmacies and can be obtained through mail-back programs. Some municipalities also offer sharps collection at pharmacies, fire stations, or designated drop-off sites.

• Removing pen too early: Wait for both clicks (start and finish) plus 5 seconds; check for gray plunger visible in clear base
• Injecting cold medication: Always allow 30 minutes at room temperature; cold injections increase discomfort and injection site reactions
• Not rotating injection sites: Use a systematic rotation pattern; avoid the same spot two weeks in a row to prevent lipodystrophy
• Injecting into muscle: In lean individuals, pinch the skin to create a subcutaneous fold; inject into the pinched tissue
• Skipping the alcohol swab: Cleaning the injection site reduces infection risk; allow the alcohol to dry completely before injecting
• Incorrect storage: Keep refrigerated until use; never freeze; track room temperature exposure (21-day maximum)
• Improper disposal: Use a sharps container for all used pens; never throw in regular trash or recycling
• Rushing dose escalation: Follow the 4-week minimum between dose increases; faster escalation worsens GI side effects and increases dropout

References

1. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1) (2022) — PubMed
2. Mounjaro (tirzepatide) injection prescribing information — Eli Lilly and Company (2024)
3. Zepbound (tirzepatide) injection prescribing information — Eli Lilly and Company (2024)
4. Subcutaneous injection technique: a systematic review and meta-analysis (2019) — PubMed
5. Lipodystrophy at injection sites: pathophysiology, prevention, and management (2021) — PubMed